Perspective Therapeutics's biggest risks in the FY2024 10-K
- Clinical-trial enrollment delays and unfavorable results threaten development of VMT-α-NET, VMT01, PSV359 and other candidates.
- Commercial success depends on physician, hospital, patient and payer acceptance, reimbursement and sales execution.
- Foreign approvals, Medicare reimbursement cuts and information-security breaches could materially harm operations.
The risks most specific to Perspective Therapeutics
- Risks Related to Our Business and Industry
Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our program candidates and may result in additional net losses
Enrollment delays or unfavorable later-stage results could increase costs, delay or prevent clinical-trial completion, and generate additional losses.
- Risks Related to Our Business and Industry
Any of these events could prevent us from achieving or maintaining market acceptance of the particular program, if approved, and could significantly harm our business, results of operations and prospects
Weak sales execution or market acceptance for VMT-α-NET, VMT01, PSV359 and other candidates could leave the company without sufficient revenue.
- Risks Related to Our Business and Industry
If any program candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these programs and may not become or remain profitable
Insufficient physician, hospital, patient or payer acceptance and inadequate third-party reimbursement could prevent profitable sales of approved products.
- Risks Related to Our Business and Industry
Legal and Regulatory Risks Related to Our Operations
Information-technology disruptions or data-security breaches could impair operations and materially harm the company’s business and financial condition.
- Risks Related to Our Business and Industry
Any cuts to Medicare reimbursement which affect our program could have a material adverse effect on our business and/or our consolidated results of operations and financial condition
Medicare reimbursement cuts or longer, costlier foreign regulatory approvals could undermine program economics and international commercialization.
Risk factor headings as read
Headings as the filing states them, in filing order.
Risks Related to Our Business and Industry
- 01Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our program candidates and may result in additional net losses
- 02Any of these events could prevent us from achieving or maintaining market acceptance of the particular program, if approved, and could significantly harm our business, results of operations and prospects
- 03If any program candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these programs and may not become or remain profitable
- 04Legal and Regulatory Risks Related to Our Operations
- 05Any cuts to Medicare reimbursement which affect our program could have a material adverse effect on our business and/or our consolidated results of operations and financial condition
Other Perspective Therapeutics 10-Ks
- FY2025 10-K risk factorsRisk factors section under review
New international and multi-jurisdiction regulatory compliance risk includes fines, license suspension, price reductions, and criminal sanctions.
Filed Mar 16, 2026
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.